AI Pathology
Indica Labs HALO AI alternatives
13 tools that we compared head to head with Indica Labs HALO AI in a written verdict. Each row says who the tool suits, according to that verdict, and links to the full comparison.
The list is not a ranking. Tools in the same category come first, then every group is in alphabetical order. A tool that is no longer sold is left out.
aetherAI
Hema and Endo modules carry Taiwan TFDA approval; iHC quantification and cell counting apps, vendor-described
See the review for plans
Full comparison
Aiforia
CE-IVD prostate AI plus breast, lung, colon suites; sOC 2 Type II and ISO 27001 published
See the review for plans
Full comparison
Artera
ArteraAI Breast cleared as K254115 on May 4, 2026; no extra staining beyond existing H&E slides
See the review for plans
Full comparison
Caris Life Sciences
MI Cancer Seek PMA P240010 approved November 5, 2024; 228 genes plus MSI and TMB from FFPE tissue
See the review for plans
Full comparison
Freenome
Vendor-reported 81.1% sensitivity for colorectal cancer; vendor-reported 90.4% specificity, advanced neoplasia
See the review for plans
Full comparison
GRAIL
Multi-cancer blood test, prescription only; run in GRAIL's own CLIA laboratory
See the review for plans
Full comparison
Ibex Medical Analytics
FDA 510(k) K241232 for Ibex Prostate Detect; prostate, breast and gastric AI on one platform
See the review for plans
Full comparison
PathAI AISight
AISight Dx cleared for primary diagnosis, K243391; cloud-native image management system
See the review for plans
Full comparison
Proscia Concentriq
SOC 2 Type II announced December 2025; concentriq AP-Dx holds two FDA 510(k) clearances
See the review for plans
Full comparisonSectra Pathology
Pathology, radiology and genomics images in one platform; marketplace of 50+ AI vendors, per Sectra
See the review for plans
Full comparison
Tempus Digital Pathology
Paige Prostate Detect holds FDA De Novo DEN200080; fullFocus viewer holds FDA 510(k) K241273
See the review for plans
Full comparison
Vesta
Vendor says report in about 3 days; recurrence and progression scores for bladder cancer
See the review for plans
Full comparison
Visiopharm
Vendor-stated IVDR apps for ER, PR, HER2 and Ki-67; 2025 HER2-low agreement study with breast pathologists
See the review for plans
Full comparison